Lupin protein isolate and cysteine-supplemented casein reduce calcification of atherosclerotic lesions in apoE-deficient mice.
Protein from lupin is supposed to have anti-atherogenic effects due to its lipid-lowering properties in laboratory animals. It is further suggested that the amino acid cysteine plays a crucial role in this aspect. The objective of the present study was to compare the effects of lupin protein and cysteine-supplemented casein with those of casein on atherosclerotic lesion development in apoE-deficient mice. For that purpose, thirty mice were fed an egg albumin-based Western-type diet containing test protein (100 g/kg) for 4 months. ApoE-deficient mice fed the lupin protein or the cysteine-supplemented casein had more than 50 % less aortic calcification than mice fed casein (P < 0.05). The quantified lesion area as a percentage of the total surface area, as well as the collagen and fat content of the lesions were not different between the three groups of mice. The concentration of VLDL TAG was higher in mice fed the lupin protein and the cysteine-supplemented casein than in mice fed casein (P < 0.05). The cholesterol concentrations of VLDL, LDL and HDL from mice fed the lupin protein and cysteine-supplemented casein were not different compared with the mice fed casein. Also, the plasma concentrations of homocysteine, Ca, inorganic phosphate, and the activity of glutathione peroxidase in plasma and liver did not differ between the three groups of mice. The present study shows that lupin protein and cysteine-supplemented casein compared with casein reduce the calcification of atherosclerotic lesions in apoE-deficient mice. This effect seems not to be mediated by effects on plasma lipoproteins, homocysteine and circulating minerals.
Weisse
Kristin
K
Institute of Agricultural and Nutritional Sciences, Martin Luther University Halle-Wittenberg, Von Danckelmann Platz 2, D-06120 Halle (Saale), Germany.
Brandsch
Corinna
C
Hirche
Frank
F
Eder
Klaus
K
Stangl
Gabriele I
GI
D015720:5'-Nucleotidase / Q000302:isolation & purification* / Q000494:pharmacology* / Q000627:therapeutic use; D000596:Amino Acids / Q000032:analysis; D000821:Animal Feed; D000818:Animals; D001057:Apolipoproteins E / Q000172:deficiency*; D050197:Atherosclerosis / Q000473:pathology / Q000517:prevention & control*; D002114:Calcinosis / Q000517:prevention & control*; D002364:Caseins / Q000494:pharmacology*; D003553:Cystine / Q000494:pharmacology*; D017931:DNA Primers; D004044:Dietary Proteins / Q000008:administration & dosage; D004195:Disease Models, Animal; D002149:Energy Intake; D008055:Lipids / Q000097:blood / Q000502:physiology; D051379:Mice; D018345:Mice, Knockout / Q000235:genetics; D014280:Triglycerides / Q000378:metabolism
D000596:Amino Acids; D001057:Apolipoproteins E; D002364:Caseins; D017931:DNA Primers; D004044:Dietary Proteins; D008055:Lipids; D014280:Triglycerides; D003553:Cystine; D015720:5'-Nucleotidase; C503010:Nt5c3 protein, mouse